By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Biomedicine and Biomedical Engineering are presented in a new report. According to news reporting from Singapore, Singapore, by NewsRx journalists, research stated, "Scaffolds based on decellularized adipose tissue (DAT) are gaining popularity in adipose tissue engineering due to their high biocompatibility and adipogenic inductive property. However, previous studies involving DAT-derived scaffolds have not fully revealed their potentials for in vivo adipose tissue construction."
The news correspondents obtained a quote from the research from Singapore National University, "With the aimof developing a more efficient adipose tissue engineering technique based on DAT, in this study, we investigated the in vivo adipogenic potential of a basic fibroblast growth factor (bFGF) delivery system based on heparinized DAT (Hep-DAT). To generate this system, heparins were cross-linked to mouse DATs by using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide and N-Hydroxysuccinimide. The bFGF-binding Hep-DATs were first tested for controlled release ability in vitro and then transplanted subcutaneously. Highly vascularized adipose tissues were formed 6 weeks after transplantation. Histology and gene expression analysis revealed that majority of the Hep-DAT scaffolds were infiltrated with host-derived adipose tissues that possessed similar adipogenic and inflammatory gene expression as endogenous adipose tissues. Additionally, strong de novo adipogenesis could also be induced when bFGF-binding Hep-DATs were thoroughly minced and injected subcutaneously."
According to the news reporters, the research concluded: "Our study demonstrated that bFGF-binding Hep-DAT could be an efficient, biocompatible and injectable adipogenic system for in vivo adipose tissue engineering."
For more information on this research see: Delivery of basic fibroblast growth factors from heparinized decellularized adipose tissue stimulates potent de novo adipogenesis. Journal of Controlled Release, 2014;174():43-50. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting Q.Q. Lu, Singapore National University, NUS Grad Sch Integrat Sci & Engn, Singapore 119083, Singapore. Additional authors for this research include M.M. Li, Y. Zou and T. Cao (see also Biomedicine and Biomedical Engineering).
Keywords for this news article include: Asia, Tissue Engineering, Biomedicine and Biomedical Engineering, Fibroblasts, Adipogenesis, Bioengineering
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC